99 research outputs found
The role of liver iron in hepatitis C antiviral treatment
No full text[No abstract available]Alexander J, 2007, LIVER INT, V27, P268, DOI 10.1111-j.1478-3231.2007.01449.x; Ancel D, 2009, EUR J GASTROEN HEPAT, V21, P726, DOI 10.1097-MEG.0b013e3283097699; Fujita N, 2007, J GASTROEN HEPATOL, V22, P1886, DOI 10.1111-j.1440-1746.2006.04759.x; HIRST C, 2002, COCHRANE DB SYST REV, V1, P3146; Inati A, 2005, BRIT J HAEMATOL, V130, P644, DOI 10.1111-j.1365-2141.2005.05645.x; Taher AT, 2009, ANN HEMATOL, V88, P1033, DOI 10.1007-s00277-009-0713-y11
Iron in sickle-cell disease: What have we learned over the years?
No full textOver the last four decades, monumental advances have been made in the understanding, assessment, and management of transfusion-dependent patients, which have translated into significant improvements in patient morbidity and mortality. Important lessons have been learned from extensive clinical experience of iron management in the thalassemias, but greater knowledge of key differences in the sickle-cell disease (SCD) population may impact on our approach to patient assessment and management. The unique pathophysiology of SCD is reflected in a distinct pattern of iron loading with minimal organ-specific injury. An appreciation and understanding of these differences should allow us to develop tailored management approaches that optimize patient outcomes. © 2010 Wiley-Liss, Inc.Abetz LN, 2005, LEUKEMIA RES, V29, pS54, DOI 10.1016-S0145-2126(05)80143-2; Adamkiewicz TV, 2009, BLOOD, V114, P4632, DOI 10.1182-blood-2009-02-203323; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056-NEJM199807023390102; Adams RJ, 2005, NEW ENGL J MED, V353, P2769; Aduloju SO, 2008, BLOOD, V112; Alvarez O, 2009, J PEDIAT HEMATOL ONC, V31, P739, DOI 10.1097-MPH.0b013e3181b53363; Anderson GJ, 2007, AM J HEMATOL, V82, P1128, DOI 10.1002-ajh.21075; Andrews NC, 2008, BLOOD, V112, P219, DOI 10.1182-blood-2007-12-077388; Angelucci E, 2000, NEW ENGL J MED, V343, P327, DOI 10.1056-NEJM200008033430503; Ballas SK, 2001, SEMIN HEMATOL, V38, P30, DOI 10.1016-S0037-1963(01)90058-7; Batra AS, 2002, AM J HEMATOL, V70, P306, DOI 10.1002-ajh.10154; Borgna-Pignatti C, 1998, ANN NY ACAD SCI, V850, P227, DOI 10.1111-j.1749-6632.1998.tb10479.x; Bourantas KL, 1998, EUR J HAEMATOL, V61, P49; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002-ajh.2830420116; Britton RS, 2002, INT J HEMATOL, V76, P219, DOI 10.1007-BF02982791; Brown K, 2009, J PEDIAT HEMATOL ONC, V31, P309, DOI 10.1097-MPH.0b013e3181a1c143; Cabantchik ZI, 2005, BEST PRACT RES CL HA, V18, P277, DOI 10.1016-j.beha.2004.10.003; Cancado R, 2009, HAEMATOLOGICA, V94; Cappellini MD, 2009, HAEMATOLOGICA, V95, P557; Casella JF, 2010, PEDIATR HEMAT ONCOL, V27, P69, DOI 10.3109-08880010903360367; CHAPMAN RWG, 1982, J CLIN PATHOL, V35, P487, DOI 10.1136-jcp.35.5.487; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056-NEJM199505183322001; Chatterjee R, 2000, CLIN ENDOCRINOL, V53, P33, DOI 10.1046-j.1365-2265.2000.00962.x; Chirnomas D, 2009, BLOOD, V114, P4009, DOI 10.1182-blood-2009-05-222729; CHIU D, 1990, AM J PEDIAT HEMATOL, V12, P262; Claster S, 2003, BRIT MED J, V327, P1151, DOI 10.1136-bmj.327.7424.1151; COHEN A, 1979, AM J HEMATOL, V7, P69, DOI 10.1002-ajh.2830070109; COHEN A, 1978, J PEDIATR, V92, P659, DOI 10.1016-S0022-3476(78)80317-5; Cohen Alan R, 2004, Hematology Am Soc Hematol Educ Program, P14; COHEN AR, 1989, J PEDIATR, V115, P151, DOI 10.1016-S0022-3476(89)80353-1; COHEN AR, 1992, BLOOD, V79, P1657; Dzik WH, 2002, CURR OPIN HEMATOL, V9, P521, DOI 10.1097-01.MOH.0000028593.70519.54; FILLET G, 1989, BLOOD, V74, P844; Fung EB, 2006, BRIT J HAEMATOL, V135, P574, DOI 10.1111-j.1365-2141.2006.06332.x; Fung EB, 2008, TRANSFUSION, V48, P1971, DOI 10.1111-j.1537-2995.2008.01775.x; Fung EB, 2007, AM J HEMATOL, V82, P255, DOI 10.1002-ajh.20809; Gabutti V, 1996, ACTA HAEMATOL-BASEL, V95, P26; Ghugre NR, 2009, AM J HEMATOL, V84, P480, DOI 10.1002-ajh.21456; Harmatz P, 2000, BLOOD, V96, P76; Hoffbrand AV, 1998, BLOOD, V91, P295; Hoppe CC, 2001, CURR OPIN ONCOL, V13, P85, DOI 10.1097-00001622-200103000-00001; Inati A, 2010, BLOOD, V115, P2980, DOI 10.1182-blood-2009-09-243568; Inati A, 2011, INT J LAB HEMATOL, V33, P133, DOI 10.1111-j.1751-553X.2010.01224.x; Inati A, 2009, EUR J HAEMATOL, V83, P565, DOI 10.1111-j.1600-0609.2009.01345.x; Jensen PD, 2003, BLOOD, V101, P91, DOI 10.1182-blood-2002-06-1704; Karam LB, 2008, PEDIATR BLOOD CANCER, V50, P62, DOI 10.1002-pbc.21215; Kersten MJ, 1996, ANN HEMATOL, V73, P247, DOI 10.1007-s002770050236; Koren A, 2010, EUR J HAEMATOL, V84, P72, DOI 10.1111-j.1600-0609.2009.01342.x; Kushner J. P., 2001, SECONDARY IRON OVERL, P47; Liem RI, 2008, BLOOD, V112; Ludwiczek S, 2003, BLOOD, V101, P4148, DOI 10.1182-blood-2002-08-2459; Modell B, 2000, LANCET, V355, P2051, DOI 10.1016-S0140-6736(00)02357-6; Morgan EH, 2002, BLOOD CELL MOL DIS, V29, P384, DOI 10.1006-bcmd.2002.0578; National Institutes of Health National Heart Lung and Blood Institute. Global initiative for asthma, 2002, NIH PUBL; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126-science.1104742; Olivieri NF, 1999, NEW ENGL J MED, V341, P99, DOI 10.1056-NEJM199907083410207; OLIVIERI NF, 1995, NEW ENGL J MED, V332, P918, DOI 10.1056-NEJM199504063321404; Olivieri NF, 2001, SEMIN HEMATOL, V38, P57, DOI 10.1053-shem.2001.20144; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056-NEJM199409013310903; PAKBAZ Z, 2004, BLOOD 2, V104, pB33; Papanikolaou G, 2005, TOXICOL APPL PHARM, V202, P199, DOI 10.1016-j.taap.2004.06.021; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172-JCI111464; Platzbecker U, 2008, BIOL BLOOD MARROW TR, V14, P1217, DOI 10.1016-j.bbmt.2008.08.006; PORTER JB, 1987, ACTA HAEMATOL-BASEL, V78, P198; Porter JB, 2001, BRIT J HAEMATOL, V115, P239, DOI 10.1046-j.1365-2141.2001.03195.x; Pullarkat V, 2008, BONE MARROW TRANSPL, V42, P799, DOI 10.1038-bmt.2008.262; Raman SV, 2006, HAEMATOL-HEMATOL J, V91, P1329; Schnog JB, 2004, NETH J MED, V62, P364; SEARS DA, 1966, BLOOD-J HEMATOL, V28, P708; Segal Jodi B, 2008, Evid Rep Technol Assess (Full Rep), P1; Sickle Cell Society, 2008, STAND CLIN CAR AD SI; SILLIMAN CC, 1993, J LAB CLIN MED, V122, P48; Singer ST, 1999, J CLIN APHERESIS, V14, P122, DOI 10.1002-(SICI)1098-1101(1999)14:3122::AID-JCA33.0.CO;2-A; Steinberg MH, 2003, JAMA-J AM MED ASSOC, V289, P1645, DOI 10.1001-jama.289.13.1645; STYLES LA, 1994, J PEDIATR, V125, P909, DOI 10.1016-S0022-3476(05)82006-2; Sumoza A, 2002, AM J HEMATOL, V71, P161, DOI 10.1002-ajh.10205; Taher A, 2008, HAEMATOL-HEMATOL J, V93, P1584, DOI 10.3324-haematol.13098; Taher A, 2009, BRIT J HAEMATOL, V147, P752, DOI 10.1111-j.1365-2141.2009.07908.x; Teixeira AL, 2002, J PEDIAT HEMATOL ONC, V24, P125, DOI 10.1097-00043426-200202000-00013; Telfer PT, 2000, BRIT J HAEMATOL, V110, P971, DOI 10.1046-j.1365-2141.2000.02298.x; Thornburg CD, 2009, PEDIATR BLOOD CANCER, V52, P609, DOI 10.1002-pbc.21738; Treadwell MJ, 2001, SEMIN HEMATOL, V38, P77, DOI 10.1053-shem.2001.20148; Treadwell MJ, 2005, PEDIATR BLOOD CANCER, V44, P500, DOI 10.1002-pbc.20290; Verduzco LA, 2009, BLOOD, V114, P5117, DOI 10.1182-blood-2009-05-220921; Vichinsky E, 2007, BRIT J HAEMATOL, V136, P501, DOI 10.1111-j.1365-2141.2006.06455.x; Vichinsky E, 2009, HAEMATOLOGICA, V94; Vichinsky E, 2005, AM J HEMATOL, V80, P70, DOI 10.1002-ajh.20402; Vichinsky E, 2008, ACTA HAEMATOL-BASEL, V119, P133, DOI 10.1159-000125550; Voskaridou E, 2004, BRIT J HAEMATOL, V126, P736, DOI 10.1111-j.1365-2141.2004.05104.x; Voskaridou E, 2005, ANN HEMATOL, V84, P434, DOI 10.1007-s00277-005-1015-7; Voskaridou E, 2010, BLOOD, V115, P2354, DOI 10.1182-blood-2009-05-221333; Voskaridou E, 2009, HAEMATOLOGICA, V94; Walter PB, 2006, BRIT J HAEMATOL, V135, P254, DOI 10.1111-j.1365-2141.2006.06277.x; Walter PB, 2009, ACTA HAEMATOL-BASEL, V122, P174, DOI 10.1159-000243802; Walters MC, 2000, BLOOD, V95, P1918; WANG WC, 1991, J PEDIATR-US, V118, P377, DOI 10.1016-S0022-3476(05)82150-X; Weatherall DJ, 2001, B WORLD HEALTH ORGAN, V79, P704; WHITTEN CF, 1962, NEW ENGL J MED, V266, P529, DOI 10.1056-NEJM196203152661102; Wood JC, 2005, BLOOD, V106, P1460, DOI 10.1182-blood-2004-10-3982; Wood JC, 2004, BLOOD, V103, P1934, DOI 10.1182-blood-2003-06-1919; ZURLO MG, 1989, LANCET, V2, P2767
Sickle cell disease: New insights into pathophysiology and treatment
No full text[No abstract available]Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056-NEJM199807023390102; Anthi A, 2007, AM J RESP CRIT CARE, V175, P1272, DOI 10.1164-rccm.200610-1498OC; Ballas SK, 2005, HEMATOL ONCOL CLIN N, V19, P785, DOI 10.1016-j.hoc.2005.07.008; Ballas Samir K, 2007, Hematology Am Soc Hematol Educ Program, P97; Bernaudin F, 2007, BLOOD, V110, P2749, DOI 10.1182-blood-2007-03-079665; Boyd JH, 2006, BLOOD, V108, P2923, DOI 10.1182-blood-2006-01-011072; Boyd JH, 2007, HAEMATOL-HEMATOL J, V92, P1115, DOI 10.3324-haematol.11213; Burnett AL, 2006, UROLOGY, V67, P1043, DOI 10.1016-j.urology.2005.11.045; CAO A, 1987, Blood Reviews, V1, P169, DOI 10.1016-0268-960X(87)90032-4; CHARACHE S, 1992, BLOOD, V79, P2555; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056-NEJM199505183322001; Chiang EY, 2005, HEMATOL ONCOL CLIN N, V19, P771, DOI 10.1016-j.hoc.2005.08.002; Cokic VP, 2003, J CLIN INVEST, V111, P231, DOI 10.1172-JCI200316672; DeSimone J, 2002, BLOOD, V99, P3905, DOI 10.1182-blood.V99.11.3905; Finnegan EM, 2007, AM J PHYSIOL-HEART C, V293, pH1038, DOI 10.1152-ajpheart.01054.2006; FRENETTE PS, 2007, CLIN INVESTIGATOR, V117, P850; Givens M, 2007, J EMERG MED, V32, P239, DOI 10.1016-j.jemermed.2006.07.022; Gladwin MT, 2003, CIRCULATION, V107, P271, DOI 10.1161-01.CIR.0000044943.12533.A8; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056-NEJMoa035477; Gulbis B, 2005, BLOOD, V105, P2685, DOI 10.1182-blood-2004-07-2704; Halasa NB, 2007, CLIN INFECT DIS, V44, P1428, DOI 10.1086-516781; Hankins JS, 2005, BLOOD, V106, P2269, DOI 10.1182-Blood-2004-12-4973; Hankins JS, 2008, PEDIATR BLOOD CANCER, V50, P293, DOI 10.1002-pbc.21271; Haque AK, 2002, HUM PATHOL, V33, P1037, DOI 10.1053-hupa.2002.128059; Hoppe C, 2007, STROKE, V38, P2241, DOI 10.1161-STROKEAHA.107.483115; Inati A, 2007, INT J LAB HEMATOL, V29, P399, DOI 10.1111-j.1751-553X.2007.00964.x; INATI A, 2006, CLIN LAB HAEMATOL, V28, P2172; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038-180326a0; Iyamu EW, 2005, BRIT J HAEMATOL, V131, P389, DOI 10.1111-j.1365-2141.2005.05772.x; KATO GJ, 2007, EHA; Kinney TR, 1999, BLOOD, V94, P1550; Kuypers Frans A, 2007, Hematology Am Soc Hematol Educ Program, P68; Loscalzo J, 2001, CIRC RES, V88, P756, DOI 10.1161-hh0801.089861; Machado RF, 2005, BRIT J HAEMATOL, V130, P445, DOI 10.1111-j.1365-2141.2005.05625.x; Miller ST, 2000, NEW ENGL J MED, V342, P83, DOI 10.1056-NEJM200001133420203; Miller ST, 2001, J PEDIATR-US, V139, P385, DOI 10.1067-mpd.2001.117580; Morris CR, 2005, JAMA-J AM MED ASSOC, V294, P81, DOI 10.1001-jama.294.1.81; Nolan VG, 2005, BLOOD, V106, P3264, DOI 10.1182-blood-2005-04-1594; Ohene-Frempong K, 1998, BLOOD, V91, P288; Panepinto JA, 2007, BRIT J HAEMATOL, V137, P479, DOI 10.1111-j.1365-2141.2007.06592.x; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126-science.110.2865.543; PERRINE RP, 1978, ANN INTERN MED, V88, P1; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056-NEJM199406093302303; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172-JCI111464; Quinn CT, 2004, BLOOD, V103, P4023, DOI 10.1182-blood-2003-11-3758; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038-nm799; Saleh AW, 1999, ACTA HAEMATOL-BASEL, V102, P31, DOI 10.1159-000040964; Serjeant G R, 1995, Curr Opin Hematol, V2, P103; Steinberg MH, 1999, NEW ENGL J MED, V340, P1021; Steinberg MH, 2003, JAMA-J AM MED ASSOC, V289, P1645, DOI 10.1001-jama.289.13.1645; Stuart MJ, 2004, LANCET, V364, P1343, DOI 10.1016-S0140-6736(04)17192-4; Styles LA, 2000, BLOOD, V96, P3276; Tamouza R, 2007, HUM IMMUNOL, V68, P849, DOI 10.1016-j.humimm.2007.08.260; Telen Marilyn J, 2007, Hematology Am Soc Hematol Educ Program, P84; TELFER P, HAEMATOLOGICA, V92, P905; Vichinsky E, 2001, SEMIN HEMATOL, V38, P1, DOI 10.1016-S0037-1963(01)90053-8; Vichinsky EP, 1997, BLOOD, V89, P1787; Vichinsky EP, 2000, NEW ENGL J MED, V342, P1855, DOI 10.1056-NEJM200006223422502; Weinberg RS, 2005, BLOOD, V105, P1807, DOI 10.1182-blood-2004-02-0454; Zimmerman SA, 2007, BLOOD, V110, P1043, DOI 10.1182-blood-2006-11-05789346
817 SUBCUTANEOUS DEFEROXAMINE (ScDF) PLUS HYPERTRANSFUSION (HiTx) IN THALASSEMIA MAJOR (TM): A THREE YEAR FOLLOW-UP
No full textSickle cell disease: New insights into pathophysiology and treatment
No full text[No abstract available]Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056-NEJM199807023390102; Anthi A, 2007, AM J RESP CRIT CARE, V175, P1272, DOI 10.1164-rccm.200610-1498OC; Ballas SK, 2005, HEMATOL ONCOL CLIN N, V19, P785, DOI 10.1016-j.hoc.2005.07.008; Ballas Samir K, 2007, Hematology Am Soc Hematol Educ Program, P97; Bernaudin F, 2007, BLOOD, V110, P2749, DOI 10.1182-blood-2007-03-079665; Boyd JH, 2006, BLOOD, V108, P2923, DOI 10.1182-blood-2006-01-011072; Boyd JH, 2007, HAEMATOL-HEMATOL J, V92, P1115, DOI 10.3324-haematol.11213; Burnett AL, 2006, UROLOGY, V67, P1043, DOI 10.1016-j.urology.2005.11.045; CAO A, 1987, Blood Reviews, V1, P169, DOI 10.1016-0268-960X(87)90032-4; CHARACHE S, 1992, BLOOD, V79, P2555; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056-NEJM199505183322001; Chiang EY, 2005, HEMATOL ONCOL CLIN N, V19, P771, DOI 10.1016-j.hoc.2005.08.002; Cokic VP, 2003, J CLIN INVEST, V111, P231, DOI 10.1172-JCI200316672; DeSimone J, 2002, BLOOD, V99, P3905, DOI 10.1182-blood.V99.11.3905; Finnegan EM, 2007, AM J PHYSIOL-HEART C, V293, pH1038, DOI 10.1152-ajpheart.01054.2006; FRENETTE PS, 2007, CLIN INVESTIGATOR, V117, P850; Givens M, 2007, J EMERG MED, V32, P239, DOI 10.1016-j.jemermed.2006.07.022; Gladwin MT, 2003, CIRCULATION, V107, P271, DOI 10.1161-01.CIR.0000044943.12533.A8; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056-NEJMoa035477; Gulbis B, 2005, BLOOD, V105, P2685, DOI 10.1182-blood-2004-07-2704; Halasa NB, 2007, CLIN INFECT DIS, V44, P1428, DOI 10.1086-516781; Hankins JS, 2005, BLOOD, V106, P2269, DOI 10.1182-Blood-2004-12-4973; Hankins JS, 2008, PEDIATR BLOOD CANCER, V50, P293, DOI 10.1002-pbc.21271; Haque AK, 2002, HUM PATHOL, V33, P1037, DOI 10.1053-hupa.2002.128059; Hoppe C, 2007, STROKE, V38, P2241, DOI 10.1161-STROKEAHA.107.483115; Inati A, 2007, INT J LAB HEMATOL, V29, P399, DOI 10.1111-j.1751-553X.2007.00964.x; INATI A, 2006, CLIN LAB HAEMATOL, V28, P2172; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038-180326a0; Iyamu EW, 2005, BRIT J HAEMATOL, V131, P389, DOI 10.1111-j.1365-2141.2005.05772.x; KATO GJ, 2007, EHA; Kinney TR, 1999, BLOOD, V94, P1550; Kuypers Frans A, 2007, Hematology Am Soc Hematol Educ Program, P68; Loscalzo J, 2001, CIRC RES, V88, P756, DOI 10.1161-hh0801.089861; Machado RF, 2005, BRIT J HAEMATOL, V130, P445, DOI 10.1111-j.1365-2141.2005.05625.x; Miller ST, 2000, NEW ENGL J MED, V342, P83, DOI 10.1056-NEJM200001133420203; Miller ST, 2001, J PEDIATR-US, V139, P385, DOI 10.1067-mpd.2001.117580; Morris CR, 2005, JAMA-J AM MED ASSOC, V294, P81, DOI 10.1001-jama.294.1.81; Nolan VG, 2005, BLOOD, V106, P3264, DOI 10.1182-blood-2005-04-1594; Ohene-Frempong K, 1998, BLOOD, V91, P288; Panepinto JA, 2007, BRIT J HAEMATOL, V137, P479, DOI 10.1111-j.1365-2141.2007.06592.x; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126-science.110.2865.543; PERRINE RP, 1978, ANN INTERN MED, V88, P1; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056-NEJM199406093302303; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172-JCI111464; Quinn CT, 2004, BLOOD, V103, P4023, DOI 10.1182-blood-2003-11-3758; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038-nm799; Saleh AW, 1999, ACTA HAEMATOL-BASEL, V102, P31, DOI 10.1159-000040964; Serjeant G R, 1995, Curr Opin Hematol, V2, P103; Steinberg MH, 1999, NEW ENGL J MED, V340, P1021; Steinberg MH, 2003, JAMA-J AM MED ASSOC, V289, P1645, DOI 10.1001-jama.289.13.1645; Stuart MJ, 2004, LANCET, V364, P1343, DOI 10.1016-S0140-6736(04)17192-4; Styles LA, 2000, BLOOD, V96, P3276; Tamouza R, 2007, HUM IMMUNOL, V68, P849, DOI 10.1016-j.humimm.2007.08.260; Telen Marilyn J, 2007, Hematology Am Soc Hematol Educ Program, P84; TELFER P, HAEMATOLOGICA, V92, P905; Vichinsky E, 2001, SEMIN HEMATOL, V38, P1, DOI 10.1016-S0037-1963(01)90053-8; Vichinsky EP, 1997, BLOOD, V89, P1787; Vichinsky EP, 2000, NEW ENGL J MED, V342, P1855, DOI 10.1056-NEJM200006223422502; Weinberg RS, 2005, BLOOD, V105, P1807, DOI 10.1182-blood-2004-02-0454; Zimmerman SA, 2007, BLOOD, V110, P1043, DOI 10.1182-blood-2006-11-05789346
Iron chelation therapy for patients with sickle cell disease and iron overload
No full textA 21-year-old male with sickle cell disease (SCD) presented with severe pallor. He had received a total of 100 red blood cell (RBC) units in his lifetime, had a mean serum ferritin level of 3133 ng-ml, and liver iron concentration (LIC) of 12 mg Fe-g dry weight (dw). He was started on subcutaneous deferoxamine (DFO) infusions at a dose of 56 mg-kg-d, five days a week (equivalent to 40 mg-kg-d, seven days a week) and continued to receive 8-10 RBC units-year as treatment for pain. During the first six months of chelation therapy, his serum ferritin levels fell by around 50percent of the pretreatment value, but then started to increase back up to the baseline values. The patient was noncompliant with DFO therapy. He experienced pain at the site of injection, could not sleep and was concerned about carrying a pump and not being accepted by his peers. He dropped out of college and abstained from all social activities. He was referred to a psychologist; however, this failed to improve compliance and he opted to stop DFO therapy altogether. © 2010 Wiley-Liss, Inc.Abetz L, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186-1477-7525-4-73; Adamkiewicz TV, 2009, BLOOD, V114, P4632, DOI 10.1182-blood-2009-02-203323; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056-NEJM199807023390102; Adams RJ, 2005, NEW ENGL J MED, V353, P2769; ALREFAIE FN, 1995, BRIT J HAEMATOL, V91, P224, DOI 10.1111-j.1365-2141.1995.tb05274.x; Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056-NEJM199912233412607; Angelucci E, 2008, HAEMATOL-HEMATOL J, V93, P741, DOI 10.3324-haematol.12413; Aydinok Y, 2005, PEDIATR INT, V47, P84, DOI 10.1111-j.1442-200x.2004.02009.x; Ballas SK, 2001, SEMIN HEMATOL, V38, P30, DOI 10.1016-S0037-1963(01)90058-7; Borgna-Pignatti C, 1998, ANN NY ACAD SCI, V850, P227, DOI 10.1111-j.1749-6632.1998.tb10479.x; BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056-NEJM199409013310902; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002-ajh.2830420116; Brown K, 2009, J PEDIAT HEMATOL ONC, V31, P309, DOI 10.1097-MPH.0b013e3181a1c143; Cabantchik ZI, 2005, BEST PRACT RES CL HA, V18, P277, DOI 10.1016-j.beha.2004.10.003; CANCADO R, 2009, HAEMATOLOGICA S2, V94; Cappellini MD, 2010, HAEMATOL-HEMATOL J, V95, P557, DOI 10.3324-haematol.2009.014696; Cappellini MD, 2006, BLOOD, V107, P3455, DOI 10.1182-blood-2005-08-3430; COHEN A, 1979, AM J HEMATOL, V7, P69, DOI 10.1002-ajh.2830070109; COHEN A, 1978, J PEDIATR, V92, P659, DOI 10.1016-S0022-3476(78)80317-5; COHEN AR, 1989, J PEDIATR, V115, P151, DOI 10.1016-S0022-3476(89)80353-1; COLLINS AF, 1994, BLOOD, V83, P2329; Darbari DS, 2006, AM J HEMATOL, V81, P858, DOI 10.1002-ajh.20685; *FERR, 2007, FERR PRESCR INF; FILLET G, 1989, BLOOD, V74, P844; Fung EB, 2006, BRIT J HAEMATOL, V135, P574, DOI 10.1111-j.1365-2141.2006.06332.x; Fung EB, 2007, AM J HEMATOL, V82, P255, DOI 10.1002-ajh.20809; Harmatz P, 2000, BLOOD, V96, P76; Hoffbrand AV, 1998, BLOOD, V91, P295; Hoffbrand AV, 2003, BLOOD, V102, P17, DOI 10.1182-blood-2002-06-1867; Inati A, 2010, BLOOD, V115, P2980, DOI 10.1182-blood-2009-09-243568; Inati A, 2009, EUR J HAEMATOL, V83, P565, DOI 10.1111-j.1600-0609.2009.01345.x; INATI A, 2010, INT J LAB HEMATOL, DOI DOI 10.1111-J.1751-553X.2010.01255.X; KALPATTHI R, 2008, BLOOD, V112; Karam LB, 2008, PEDIATR BLOOD CANCER, V50, P62, DOI 10.1002-pbc.21215; Kersten MJ, 1996, ANN HEMATOL, V73, P247, DOI 10.1007-s002770050236; Koren A, 2010, EUR J HAEMATOL, V84, P72, DOI 10.1111-j.1600-0609.2009.01342.x; Leonard MB, 1998, J PEDIATR, V132, P467, DOI 10.1016-S0022-3476(98)70022-8; Modell B, 2000, LANCET, V355, P2051, DOI 10.1016-S0140-6736(00)02357-6; Mokhtar GM, 2010, HEMOGLOBIN, V34, P78, DOI 10.3109-03630260903554621; National Institutes of Health National Heart Lung and Blood Institute. Global initiative for asthma, 2002, NIH PUBL; OLIVIERI NF, 1995, NEW ENGL J MED, V332, P918, DOI 10.1056-NEJM199504063321404; Olivieri NF, 2001, SEMIN HEMATOL, V38, P57, DOI 10.1053-shem.2001.20144; Olivieri NF, 1998, NEW ENGL J MED, V339, P417, DOI 10.1056-NEJM199808133390701; OLIVIERI NF, 1986, NEW ENGL J MED, V314, P869, DOI 10.1056-NEJM198604033141402; Pakbaz Z, 2007, PEDIATR BLOOD CANCER, V49, P329, DOI 10.1002-pbc.21275; PAKBAZ Z, 2004, BLOOD, V104; PORTER JB, 1987, ACTA HAEMATOL-BASEL, V78, P198; Porter JB, 2001, BRIT J HAEMATOL, V115, P239, DOI 10.1046-j.1365-2141.2001.03195.x; Porter JB, 2008, BLOOD, V112; Porter J, 2008, EUR J HAEMATOL, V80, P168, DOI 10.1111-j.1600-0609.2007.00985.x; Schmid M, 2009, BLOOD, V114; Sickle Cell Society, 2008, STAND CLIN CAR AD SI; SILLIMAN CC, 1993, J LAB CLIN MED, V122, P48; Stuart MJ, 2004, LANCET, V364, P1343, DOI 10.1016-S0140-6736(04)17192-4; Treadwell MJ, 2005, PEDIATR BLOOD CANCER, V44, P500, DOI 10.1002-pbc.20290; Verduzco LA, 2009, BLOOD, V114, P5117, DOI 10.1182-blood-2009-05-220921; Vichinsky E, 2007, BRIT J HAEMATOL, V136, P501, DOI 10.1111-j.1365-2141.2006.06455.x; VICHINSKY E, 2008, BLOOD, V112; Vichinsky E, 2005, AM J HEMATOL, V80, P70, DOI 10.1002-ajh.20402; Vichinsky E, 2008, AM J HEMATOL, V83, P398, DOI 10.1002-ajh.21119; Voskaridou E, 2005, ANN HEMATOL, V84, P434, DOI 10.1007-s00277-005-1015-7; Voskaridou E, 2009, HAEMATOLOGICA S2, V94; Voskaridou E, 2007, HAEMATOL-HEMATOL J, V92, P738, DOI 10.3324-haematol.11136; Wahl S, 2009, CURR OPIN PEDIATR, V21, P15, DOI 10.1097-MOP.0b013e328321882e; Walter PB, 2006, BRIT J HAEMATOL, V135, P254, DOI 10.1111-j.1365-2141.2006.06277.x; Wonke B, 1998, BRIT J HAEMATOL, V103, P361; Wood JC, 2004, BLOOD, V103, P1934, DOI 10.1182-blood-2003-06-1919; ZURLO MG, 1989, LANCET, V2, P2787
A rare aggravation of severe mucositis post chemotherapy in a child with acute lymphoblastic leukemia [v1; ref status: indexed, http://f1000r.es/1tf]
No full textOral mucositis is a debilitating manifestation in children undergoing chemotherapy and radiotherapy. Children with mucositis should be properly managed in order to prevent further exacerbation and adverse complications. We hereby present the first report of a severe chemotherapy-induced mucositis, plausibly aggravated by improper dental hygiene leading to shedding of the ventral part of the tongue in a child with pre-B acute lymphoblastic leukemia (ALL). The patient steadily and gradually recovered her oral maneuvers and ability to speak several months later. Her tongue underwent hypertrophy as a compensatory mechanism. We recommend that critical and regular assessment of the oral mucosa and proper dental care and oral hygiene be emphasized in all pediatric patients receiving chemotherapy. Families of affected children need to be educated about the benefits and modes of optimal oral hygiene for their children and the need to seek immediate care for mouth pain and or lesions. Optimal treatment for mucositis needs to be instituted without delay in this high risk pediatric population. Such a preventive and therapeutic approach may prevent associated life threatening oral and systemic complications, promote rapid and complete mucosal healing, alleviate pain and improve quality of life in children with cancer
Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia
No full textNon-transferrin-bound iron (NTBI) was evaluated as an index of iron overload in a cross-sectional randomised study in 74 non-transfused patients with thalassaemia intermedia (TI). Mean NTBI (2.92 ± 3.43 μmol/l), serum ferritin (1023 ± 780 ng/ml) and liver iron concentration (LIC; 9.0 ± 7.4 mg Fe/g dry weight) were increased above reference-range levels. Significant positive correlations occurred between mean NTBI and LIC (Pearson correlation 0.36; P = 0.002) and serum ferritin (Pearson correlation 0.421; P < 0.0001); with higher levels observed in splenectomised patients. NTBI assessment has potential as a simple reliable approach to determining iron status in TI
- …
